A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Rabusertib (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 27 Jun 2016 Results published in the Investigational New Drugs
- 08 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 May 2014 Planned End Date changed from 1 Apr 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.